Highlights
- 1
- 2Molecular cancer research : MCR · 2024
- 3
Publications
176 publications
Funding
13 grantsView NIH portfolio on RePORTER ↗
Active
6 grants- Co-IGenomically-informed Morphological Stromal Signatures to Predict Lethal Prostate CancerU.S. Department of Defense · 2025–2028HT9425-25-1-0385
- Sub-PIA cord-blood specific subset of human gamma-delta T cells with distinct functional featuresNational Institute of Allergy and Infectious Diseases · 2026–2028 · via University of MarylandR21AI196697-01
- Sub-PIRadiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center (Shared Resources Core)National Cancer Institute · 2022–2027 · via University of Maryland, BaltimoreU54CA273956-05
- Co-IInvestigating cell-intrinsic and extrinsic interactions in prostate cancer at the single cell level ("Core A: Pathobiology")National Cancer Institute · 2022–2027 · via Columbia UniversityP01CA265768-01
- PIResearch Collaboration Agreement with Sanofi US Services, IncSanofi S.A. · 2024–2026BioPharma AllianceBP 250339-02
- Sub-PIAnalysis of cord blood Vd2 T cell differentiation and function using CITE-seq and ATAC-seqNational Institute of Allergy and Infectious Diseases · 2024–2026 · via University of Maryland, BaltimoreR03AI182671-02
Completed grants (7)
- PICollaborative Research: SCH: Integrated Analysis of Single-Cell and Spatially Resolved Omics DataNational Science Foundation · 2021–2025NSF 213498-04
- Co-ICharacterizing 3'-UTR biology as a mechanism of therapy response in high risk prostate cancer.U.S. Department of Defense · 2024–2025HT9425-24-1-0310
- Co-IDecoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging DataU.S. Department of Defense · 2024–2024HT94252410381
- PIPilot project for ROBIN collaborativeUniversity of Maryland, Baltimore · 2024–2024UMB 240371-01
- Sub-PIPhase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)National Cancer Institute · 2020–2024 · via The Johns Hopkins UniversityR01CA235681-05
- Sub-PIBioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLCNational Cancer Institute · 2020–2023 · via The Johns Hopkins UniversityU01CA231776-05
- PIHardwiring Mechanism into Predicting Cancer Phenotypes by Computational LearningNational Cancer Institute · 2021–2023R01CA200859-06
Clinical research
2 studies
Active
2 studies- PIEmpowering Precision Medicine: Predicting Therapeutic Response in Ulcerative Colitis on Whole Slide Histopathology ImagesWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIA Research Data Repository for the Department of Pathology and Laboratory MedicineWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
News mentions
1 mentionView all WCM news ↗
- Researchers Customize AI Tools for Digital PathologyJuly 9, 2024
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.
Mentoring
1 menteeAll publications with mentees →
- WDWikum DinalankaraPostdoc mentee · 2020–2026
External relationships
Ownership
Amazon Web Services, Inc. · CRISPR Therapeutics · Grail · Moderna, Inc. · NVIDIA Corporation
Professional Services
Dana-Farber Cancer Institute · The Johns Hopkins University